UFESA donates to the Josep Carreras Leukaemia Research Institute to promote health-related research projects
The trade mark UFESA, belonging to the B&B trends group, joins the network of collaborators of the Josep Carreras Leukemia Institute
Dr. Berta Nieves Vázquez: “Being a Marie Skłodowska Curie fellow is a key step towards a stable position”
For many researchers, mobility is a way to pursue a science career. This was true for Berta Nieves Vázquez, who moved overseas after her PhD in the University of Barcelona, for her first postdoctoral experience at Rutgers University, in New Jersey (USA). Seven years of successful research later, she found herself facing one of the toughest but common decisions of an expat researcher. As the British band The Clash put it in 1982: should I stay, or should I go (back)?
Our Single Cell Unit is Sponsoring a Grant Program for Innovative Investigators
The Single Cell Unit of the Josep Carreras Leukaemia Research Institute is sponsoring Innovative Investigators at Institutions in the North East Area of Spain, in the framework of 10x Genomics Core Lab Grant Program.
Dr. Anna Bigas, among the "Top 100 Women Leaders"
The Deputy Director of Preclinical Research at the Josep Carreras Leukemia Research Institute and head of the Stem Cells and Cancer group, based at the Hospital del Mar - IMIM campus, has been selected as one of the 100 most outstanding women leaders in Spain.
Genetic variants identified that impact immune cells’ functioning
Researchers have combined genome-wide sequencing and functional profiling of immune cells to understand more about the impact of genetic variants on disease.
Discovery of Epigenetic Factors Predicting the Severity of COVID-19
An article published in the journal EBiomedicine by the group of Dr. Manel Esteller, Director of the Josep Carreras Leukaemia Research Institute and Dr. Aurora Pujol, head of the Neurometabolic Diseases Group of the Bellvitge Biomedical Research Institute (IDIBELL), shows that the epigenetic endowment of each person influences the severity of the COVID-19 disease.
Personalized and precision medicine: the future of tailored treatments discussed at PEMED 2021, chaired by the Josep Carreras Leukaemia Research Institute
Internationally renowned scientists in the field of personalized and precision medicine gather together online at PEMED 2021, chaired by the Josep Carreras Leukeaemia Research Institute, to share the latest discoveries on how individual variability modifies available treatments to complex diseases.
Sant Pau administers the first CAR-T of its own production for Hodgkin and non-Hodgkin lymphoma T in Europe
The first CAR-T immunotherapy drug produced entirely in Sant Pau (academic) and administered to the first patient is part of a pioneering clinical trial in Europe of CAR-T phase I / II immunotherapy for the autologous treatment of classical Hodgkin lymphoma and relapsed / refractory CD30 + non-Hodgkin T CD30 + lymphoma, funded by the Carlos III Health Institute and the Josep Carreras Leukaemia Foundation.
Success of the first phase-2 clinical trial testing the new CAR-T technology against multiple myeloma
The trial, with the participation of the Josep Carreras Leukemia Research Institute, shows that CAR-T technology is effective in multiple myeloma patients who have already exhausted their default treatment options.
Single-Cell Technologies and Analyses in Hematopoiesis and Hematological MalignanciesExperimental Hematology(2021), doi.org/10.1016/j.exphem.2021.05.001 9 May 2021, .
In recent years, single-cell technologies have emerged as breakthrough techniques that enable the characterization of hematopoietic cell populations of normal and malignant tissue samples and will be combined in the near future with bulk technologies, currently used in clinical practice, in order to improve diagnosis, prognosis and search for novel molecular targets. These single-cell methods have the advantage of not masking cell-to-cell variation features and involve the study of genetic, epigenetic, transcriptional and proteomic landscapes from a single-cell perspective. Latest advances in this field have enabled the development of novel strategies that significantly increase both sensitivity and high-throughput. In this review, we emphasize emerging techniques aimed at assessing individual or multi-omic parameters at single-cell resolution, and analyze how these technologies have helped us understand hematopoietic variability and identify unknown and/or rare subpopulations. We also summarize the impact of these single-cell profiling strategies on the characterization of cell diversity within the tumor, and the clonal evolution of multiple hematological malignancies in samples from untreated and treated patients, which provide valuable information for diagnosis, prognosis and future treatments, and explain why current therapies may fail. However, despite these improvements, new challenges lie ahead.
Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms.Cancers (Basel) 27 Apr 2021, 13 (9) .
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are myeloid neoplasms characterized by the presentation of overlapping features from both myelodysplastic syndromes and myeloproliferative neoplasms. Although the classification of MDS/MPN relies largely on clinical features and peripheral blood and bone marrow morphology, studies have demonstrated that a large proportion of patients (~90%) with this disease harbor somatic mutations in a group of genes that are common across myeloid neoplasms. These mutations play a role in the clinical heterogeneity of these diseases and their clinical evolution. Nevertheless, none of them is specific to MDS/MPN and current diagnostic criteria do not include molecular data. Even when such alterations can be helpful for differential diagnosis, they should not be used alone as proof of neoplasia because some of these mutations may also occur in healthy older people. Here, we intend to review the main genetic findings across all MDS/MPN overlap syndromes and discuss their relevance in the management of the patients.More information
Shikimic acid protects skin cells from UV-induced senescence through activation of the NAD+-dependent deacetylase SIRT1.Aging (Albany NY) 26 Apr 2021, 13 .
UV radiation is one of the main contributors to skin photoaging by promoting the accumulation of cellular senescence, which in turn induces a proinflammatory and tissue-degrading state that favors skin aging. The members of the sirtuin family of NAD+-dependent enzymes play an anti-senescence role and their activation suggests a promising approach for preventing UV-induced senescence in the treatment of skin aging. A two-step screening designed to identify compounds able to protect cells from UV-induced senescence through sirtuin activation identified shikimic acid (SA), a metabolic intermediate in many organisms, as a bona-fide candidate. The protective effects of SA against senescence were dependent on specific activation of SIRT1 as the effect was abrogated by the SIRT1 inhibitor EX-527. Upon UV irradiation SA induced S-phase accumulation and a decrease in p16INK4A expression but did not protect against DNA damage or increased polyploidies. In contrast, SA reverted misfolded protein accumulation upon senescence, an effect that was abrogated by EX-527. Consistently, SA induced an increase in the levels of the chaperone BiP, resulting in a downregulation of unfolded protein response (UPR) signaling and UPR-dependent autophagy, avoiding their abnormal hyperactivation during senescence. SA did not directly activate SIRT1 in vitro, suggesting that SIRT1 is a downstream effector of SA signaling specifically in the response to cellular senescence. Our study not only uncovers a shikimic acid/SIRT1 signaling pathway that prevents cellular senescence, but also reinforces the role of sirtuins as key regulators of cell proteostasis.More information
Progressive endothelial cell damage in correlation with sepsis severity. Defibrotide as a contender.J Thromb Haemost 19 Apr 2021, .
Background: The vascular endothelium plays a key role in sepsis pathophysiology and the associated organ dysfunction. Methods: We evaluated endothelial function in an experimental in-vitro model of sepsis, using endothelial cells grown in the presence of serum from patients with septic syndromes (sepsis, severe sepsis, and septic shock), non-infectious systemic inflammatory response syndrome (NI-SIRS) and healthy volunteers. Experiments were performed in the absence and presence of defibrotide (DF) (100µg/mL) to evaluate its potential protective effect. Results: After exposure to patients' sera, there was a progressive endothelial cell activation in correlation with sepsis severity, with a proinflammatory and prothrombotic phenotype, exhibiting significantly increased expression of adhesion receptors at the surface (ICAM-1, p< 0.05 and VCAM-1, p< 0.05); higher production and release to the extracellular matrix (ECM) of Von Willebrand factor (p< 0.001); augmented thrombogenicity of the ECM towards platelets (p< 0.001); and increased phosphorylation of intracellular p38MAPK. DF prevented these changes in all groups. Conclusions: Markers of endothelial damage increased progressively in association with the severity of septic syndromes. The endothelium is therefore an important therapeutic target to prevent complications of sepsis. DF shows promising potential to modulate the endothelial damage associated with sepsis and may constitute a pharmacological tool to decrease its sequelae including multiorgan failure.More information
A Single-Run Next-Generation Sequencing (NGS) Assay for the Simultaneous Detection of Both Gene Mutations and Large Chromosomal Abnormalities in Patients with Myelodysplastic Syndromes (MDS) and Related Myeloid NeoplasmsCancers 2021, 13(8), 1947 18 Apr 2021, .
Myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms are clonal disorders that share most of their cytogenetic and molecular alterations. Despite the increased knowledge of the prognostic importance of genetics in these malignancies, next-generation sequencing (NGS) has not been incorporated into clinical practice in a validated manner, and the conventional karyotype remains mandatory in the evaluation of suspected cases. However, non-informative cytogenetics might lead to an inadequate estimation of the prognostic risk. Here, we present a novel targeted NGS-based assay for the simultaneous detection of all the clinically relevant genetic alterations associated with these disorders. We validated this platform in a large cohort of patients by performing a one-to-one comparison with the lesions from karyotype and single-nucleotide polymorphism (SNP) arrays. Our strategy demonstrated an approximately 97% concordance with standard clinical assays, showing sensitivity at least equivalent to that of SNP arrays and higher than that of conventional cytogenetics. In addition, this NGS assay was able to identify both copy-neutral loss of heterozygosity events distributed genome-wide and copy number alterations, as well as somatic mutations within significant driver genes. In summary, we show a novel NGS platform that represents a significant improvement to current strategies in defining diagnosis and risk stratification of patients with MDS and myeloid-related disorders.
17 May 2021 16:00 - 19 May 2021 20:00
18 May 2021 15:00 - 16:00
Online. Mariona Graupera. Endothelial Pathobiology and Microenvironment Group. IJC.
21 May 2021 12:00 - 13:00
Online. Francesc Bosch. Vall d’Hebron Institut d’Oncologia (VHIO)
28 May 2021 12:00 - 13:00
Online. Caroline Dive, Cancer Research UK Manchester Institute, United Kingdom
1 June 2021 15:00 - 16:00
Online. Jordi Esteve. Myeloid Neoplasms Group. IJC.